In recent years, some patients with abnormal liver function came to the outpatient clinic. After checking the hepatitis series, ultrasound and CT of liver, biliary and pancreatic organs were normal, which could not explain the cause of abnormal liver function, and then inadvertently checked the ultrasound of the urinary system and found a malignant tumor in the kidney. How did this happen? It turns out that kidney cancer can also cause abnormal liver function. In 1961, Stauffer first reported that liver function abnormalities caused by kidney tumors, but no metastases in the liver, when the primary kidney tumor was removed, liver function returned to normal, called nephrogenic hepatic dysfunction syndrome. According to statistics, about 10% of renal tumors have this syndrome, most commonly renal cell carcinoma with an incidence of about 40%, followed by mixed cell carcinoma and renal sarcoma, and undifferentiated cell carcinoma has also been reported to be prone to this syndrome. In addition, it is occasionally seen in pyelonephritis complicated by hydronephrosis and yellow granulomatous pyelonephritis. In fact, Stauffer’s syndrome is a kind of paraneoplastic syndrome, which refers to the syndrome caused by tumors other than the primary lesions and metastases of tumors, rather than the direct metastasis of tumors into certain tissues and organs. It is mainly due to the immune response to hormone-like substances, toxins and biotoxic peptides secreted by tumor cells, which manifests as diffuse hepatocellular inflammation. The current diagnostic criteria for nephrogenic hepatic dysfunction syndrome are: 1. diagnosis of renal cell carcinoma; 2. exclusion of liver metastasis by ultrasound and abdominal CT; 3. exclusion of active hepatitis; 4. exclusion of drug-related liver impairment; 5. no abnormal liver function in the past 3 months due to cholecystitis or gallstones; 6. hyperbilirubinemia, increased alkaline phosphatase, increased glutamate transaminase, decreased serum protein electrophoresis albumin and increased α2 globulin. 3 out of 6 abnormalities such as decreased α2 globulin and prolonged prothrombin time. Treatment was based on resection of the renal tumor and supplemented with hepatoprotective and enzyme-lowering therapy. The discovery of this syndrome is a reminder for patients with long-standing liver impairment that the possibility of renal tumor should be considered to avoid delaying the disease due to missed diagnosis.